A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors.

This document provides information about a clinical trial for a drug called NKT3447. The trial aims to assess the safety, efficacy, and pharmacokinetic/pharmacodynamic data of NKT3447 in patients with advanced or metastatic solid tumors, including ovarian cancer, endometrial cancer, gastric cancer, small cell lung cancer, and triple-negative breast cancer. The trial will involve dose escalation and dose expansion phases to determine the maximum tolerated dose and preliminary antitumor activity. The trial is not yet recruiting participants and is estimated to be completed in May 2027. The study is being conducted in the United States by NiKang Therapeutics, Inc. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)